August November 2018
|
|
- Tracy Porter
- 5 years ago
- Views:
Transcription
1 Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer 3Q 2018 Reprt August Nvember 2018
2 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements based n uncertainty, since they relate t events and depend n circumstances that will ccur in future and which, by their nature, will have an impact n the results f peratins and the financial cnditin f Targvax. Such frward-lking statements reflect the current views f Targvax and are based n the infrmatin currently available t the cmpany. Targvax cannt give any assurance as t the crrectness f such statements. There are a number f factrs that culd cause actual results and develpments t differ materially frm thse expressed r implied in these frward-lking statements. These factrs include, amng ther things, risks r uncertainties assciated with the success f future clinical trials; risks relating t persnal injury r death in cnnectin with clinical trials r fllwing cmmercializatin f the cmpany s prducts, and liability in cnnectin therewith; risks relating t the cmpany s freedm t perate (cmpetitrs patents) in respect f the prducts it develps; risks f nn-apprval f patents nt yet granted and the cmpany s ability t adequately prtect its intellectual prperty and knw-hw; risks relating t btaining regulatry apprval and ther regulatry risks relating t the develpment and future cmmercializatin f the cmpany s prducts; risks that research and develpment will nt yield new prducts that achieve cmmercial success; risks relating t the cmpany s ability t successfully cmmercialize and gain market acceptance fr Targvax s prducts; risks relating t the future develpment f the pricing envirnment and/r regulatins fr pharmaceutical prducts; risks relating t the cmpany s ability t secure additinal financing in the future, which may nt be available n favrable terms r at all; risks relating t currency fluctuatins; risks assciated with technlgical develpment, grwth management, general ecnmic and business cnditins; risks relating t the cmpany s ability t retain key persnnel; and risks relating t the impact f cmpetitin. 2
3 Status & Highlights 2. TG ne-antigen vaccine 3. ONCOS nclytic virus prgram 4. 3Q 2018 Financials 3
4 TARGOVAX AIM IS TO ACTIVATE THE PATIENT S OWN IMMUNE SYSTEM TO FIGHT CANCER Targvax fcus Immune activatrs Onclytic viruses, vaccines Immune mdulatrs Checkpint inhibitrs Surgery - Radi - Chem Immune bsters CAR-Ts, TCRs Targeted therapy TKIs, PARPs, gene therapy, etc. 4
5 Tw prgrams in clinical develpment, with an ONCOLYTIC VIRUS LEAD PRODUCT CANDIDATE ONCOS Onclytic virus TG Neantigen vaccine Lead prduct candidate Genetically armed adenvirus Alerts the immune system t recgnize cancer antigens Induces T-cells specific t the patients tumr 4 nging trials Pipeline prduct Shared neantigen, therapeutic cancer vaccine Triggers the immune system t recgnize mutant RAS cancers 1 nging trial Triggers patientspecific respnses N need fr individualizatin 5
6 3Q 2018 HIGHLIGHTS ONCOS-102 Melanma CPI refractry phase I trial: One cmplete respnse amng first six patients Innate and adaptive immune activatin in all fur evaluated patients ONCOS-102 Peritneal cancer phase I/II trial in cmbinatin w/ Imfinzi : Safety evaluatin f first dse chrt cmpleted withut any cncerns During perid ONCOS-102 Prstate cancer phase I trial in cmbinatin w/ DCVAC: First patient has been dsed Publicatins: New ONCOS-102 in viv data in the Jurnal f Medical Virlgy, shwing T-cell activatin in a mesthelima mdel Crprate develpment: Trbjørn Furuseth appinted Chief Financial Officer, with Erik Digman Wiklund transitining t the rle f Chief Business Officer Pst-perid Full data set frm the TG01 trial in resected pancreatic cancer, including encuraging disease-free survival data was annunced 6
7 Large deals in the last year shw strng INDUSTRY INTEREST IN ONCOLYTIC VIRUSES Acquirer Target Type f deal Deal value M&A Phase I/II nclytic virus USD 250m up-frnt cash M&A Phase I/II nclytic virus USD 400m up-frnt cash M&A Pre-clinical nclytic virus USD 140m up-frnt cash Up t USD 1b ttal value 7 BD partnership Pre-clinical nclytic virus USD 15m milestne payment Up t USD 1b ttal value
8 TG ne-antigen vaccine 3. ONCOS nclytic virus prgram 4. 3Q 2018 Financials
9 The RAS gene is mutated in 90% OF PANCREATIC AND 50% OF COLORECTAL CANCERS Frequency f RAS mutatins Glbal cancer incidents per 10,000 (xx) = n. f cancer patients High Med Gallbladder (180,000) Pancreas (340,000) Melanma f skin (230,000) Prstate (1,130,000) Clrectal (1,360,000) Lung (1,820,000) RAS mutatins are ncgenic and result in uncntrlled cell divisin There are n existing therapies targeting RAS mutatins Targvax TG prgram is a unique vaccine apprach fr mutant RAS cancer Lw Fernandez-Medarde; RAS in Cancer and Develpmental Diseases; Genes & Cancer. 2011;2(3)
10 TG01 IN RESECTED PANCREATIC CANCER SIGNAL OF EFFICACY SEEN IN PHASE I/II TRIAL Median verall survival (mos) (N=32) Median disease free survival (mdfs) mutras immune activatin 33.4 vs mnths reprted in the ESPAC4 trial fr gemcitabine alne (frm time f surgery) First chrt: 33.1 mnths mos (n=19) Secnd chrt: nt yet reached (n=13) 16.1 vs mnths reprted in the ESPAC4 trial fr gemcitabine alne (frm time f surgery) First chrt 13.9 mnths mdfs (n=19) Secnd chrt 19.5 mnths mdfs (n=13) 30 ut f 32 patients (94%) had RAS-specific immune activatin Dsing and safety Dsing regimen defined and TG01 is well-tlerated in cmbinatin with chemtherapy 10
11 TG01 resected pancreas cancer trial verall survival SECOND PATIENT COHORT PERFORMING BETTER 2 nd chrt; ptimized dsing regimen 77% 2-year survival rate (10/13) mos nt yet reached 9 patients alive at time f analysis 1 st chrt; full dsing regimen 68% 2-year survival rate (13/19) mos 33.1 mnths (frm surgery) ESPAC4 mos 27.6 mnths 5 patients alive at time f analysis 11
12 DISEASE FREE SURVIVAL FROM SURGERY 2nd chrt (n=13) Median DFS 19.5 mnths ESPAC4 mdfs 13.1 mnths 1st chrt (n=19) Median DFS 13.9 mnths st chrt 2 nd chrt Censred= N prgressin n latest scan cllected 12
13 OPPORTUNITIES TO DEVELOP THE TG PROGRAM Ratinale fr further develpment f TG With the emergence f immune checkpint inhibitrs, therapeutic vaccine strategies are primed fr a rebirth Clinical relevance Well-defined target Grwing interest Meaningful clinical benefit (DFS and OS) data in resected pancreatic cancer Immune activatin with generatin f mutras specific T-cells Gd safety prfile Cancer neantigens are immungenic and can drive anti-tumr immunity RAS mutatins are knwn trunk neantigens present in large patient ppulatins Cmbinatins with CPI might fully release the therapeutic ptential f neantigen vaccines Several academic grups have cntacted Targvax t run trials with TG 13
14 TG CLINICAL DEVELOPMENT STRATEGY Resected pancreatic cancer Clrectal cancer Lung cancer (NSCLC) All mutras cancers TG01 indicatin Ph I/II cmpleted Next steps being reassessed ~ incidents TG02 lead indicatin Ph I trial nging 50% mutras ~0.5m incidents TG02 ptential future indicatin 30% mutras ~0.5m incidents TG02 + TG03 lngterm ptential Up t 30% f all cancer patients 14 Surce: Glbal data, Riva et al. Pls One 2017 Estimated ttal addressable patient number with RAS mutatins in US, EU and China
15 TG DEVELOPMENT STRATEGY OVERVIEW TG pivtal develpment Future indicatin TBD Cllabrative pancreas trial Pursue pprtunities fr investigatr-led trials in pancreatic cancer CPI cmbinatin clinical trial Evaluate clinical benefit f TG vaccinatin Scin cmbinatin with PD-1/L1 blckade Pre-clinical package Generate supprting pre-clinical TG data package, incl. CPI and ONCOS cmbinatin TG01-01 phase I/II data in pancreatic cancer TG02-01 nging phase I trial in clrectal cancer TG01 histrical Hydr Pharma data 15
16 ONCOS nclytic virus prgram 4. 3Q 2018 Financials
17 ONCOS CLINICAL DEVELOPMENT STRATEGY Path-t-market Mesthelima Prf-f-cncept CPI refractry Prf-f-cncept New CPI indicatin Next generatin nclytic viruses Target launch indicatin Indicatins with n/ limited effect f CPIs Peritneal malignancies Platfrm expansin with new targets Onging Phase I/II Orphan drug status Aim t becme additin t SC 15,000 patients per year Onging melanma Phase I Cmb w/pd-1 >100,000 patients per year Onging Phase I/II in varian and clrectal Cmb w/pd-l1 >100,000 patients per year Onging pre-clinical testing Nvel targets and mde-f-actin Brad spectrum f slid tumrs 17 SOURCE: Glbal Data, EU big 5 + US
18 ONCOS CLINICAL PROGRAM OVERVIEW Mesthelima Phase I/II - randmized 30 patients Shrtest path-t-market Orphan drug designatin Cmbinatin with SC chem Randmized vs. SC Melanma Phase I up t patients PC in CPI refractry patients Cmbinatin with Keytruda Memrial Slan Kettering Cmpassinate use prgram 115 patients Phase I trial 12 patients 7 indicatins Ovarian and clrectal cancers Peritneal cancer Cmbinatin with Imfinzi Phase I/II Intraperitneal administratin up t 78 patients Cllabratin with MedImmune / AZ, CRI, & Ludwig Cmpleted trials Onging trials spnsred by Targvax Onging trials spnsred by partner Prstate cancer Phase I up t 15 patients Cmbinatin with dendritic cell vaccine (DCVAC) Cllabratin with Sti 18
19 ONCOS-102 in malignant pleural mesthelima DEVELOPMENT STRATEGY AND INDICATIVE TIMELINES Onging Phase I/II, randmized 30 patients Planned Expansin f randmized Phase II ~60 additinal patients (N=90) Future Phase III n=tbd Randmized ORR and OS data 30 patients Decide n pssible CPI cmbinatin arm EMA & FDA advisry meetings Randmized ORR and OS data 90 patients Ptentially use as basis fr a submissin fr cnditinal apprval Ptentially start Phase III OS trial fr full MAA 19
20 ONCOS KEYTRUDA MELANOMA TRIAL One cmplete respnse bserved in the first six patients 1 Safety 2 Innate immune activatin 3 Adaptive immune activatin 4 Efficacy First safety review cmpleted with n safety cncerns ONCOS-102 first time in melanma treatment Systemic increase f several prinflammatry cytkines (6/6 patients) Increase in the relative level f cyttxic CD8+ T- cells (4/4 patients) Increase in PD-1 expressin n CD8+ T-cells (4/4 patients) Cmplete respnse in ne ut f six patients Expected <5% CR in this CPI refractry ppulatin* 20 *SOURCE: Checkmate Pharmaceutical, press release 17 April 2018
21 MELANOMA COMPLETE RESPONSE CASE EXAMPLE Received 3 injectins f ONCOS-102 and 2 Keytruda infusins Baseline Day 22 Day Tw immuntherapies received prir t study (Yervy and Keytruda)
22 3Q 2018 Financials
23 TARGOVAX HAS A SOUND FINANCIAL POSITION with cash t cmplete the planned clinical prgram int 2020 Operatins The share Cash end f 3Q - Sep 30 th NOK millin -27 NOK millin 21 USD millin Net cash flw - ttal 3Q 112 NOK millin -3 USD millin Annual run rate - last fur quarters 14 USD millin Market Cap - at share price NOK ~9 470 NOK millin 2.5 NOK millin 57 USD millin Daily turnver - rlling 6 mnth avg. Analyst cverage 0.3 USD millin DNB, ABG Sundal Cllier, Arctic, Redeye, Edisn 0.5 % f share capital 23
24 TARGOVAX IS LISTED ON THE OSLO STOCK EXCHANGE and included in the OSEBX index as f December 2017 TRVX share turnver (% f share capital, rlling 12 mnth) USD ~57 m market cap USD 0,3m avg. daily turnver in last 6 mnths USD 13m ttal turnver in 3Q 150k shares avg. daily vlume in 3Q ~ 4,000 wners 52.6m shares* (57.4 fully diluted) 24 * Up until 30 th Sep
25 R&D PIPELINE OVERVIEW AND MILESTONES Platfrm Prduct candidate Preclinical Phase I Phase II Phase III Last event Next expected event Mesthelima Cmb. w/ pemetrexed/cisplatin 1 Phase Ib safety lead-in chrt, incl. immune activatin and ORR data (6 pts) 1H 2020 Randmized ORR data 30 pts ONCOS nclytic adenvirus ONCOS-102 Melanma Cmb. w/keytruda Peritneal cancers 2,3 Cllab: Ludwig, CRI & AZ Cmb. w/imfinzi Prstate 3 Cllab: Sti Cmb. w/dcvac ORR and immune activatin (6 pts), 1/6 CR First dse escalatin chrt safety review (4 pts) First patient dsed 1H 2019 ORR and immune data first chrt Update by cllabratr, expected 2019 Update by cllabratr, expected 2019 Next-gen ONCOS 3 viruses undisclsed Virus cnstruct clning and in vitr validatin 2H 2019 Target disclsure and in viv data TG neantigen cancer vaccine TG01 TG02 TG02 Pancreatic cancer Cmb. w/gemcitabine Clrectal cancer Prf-f-mechanism Cmb. w/keytruda CPI synergy TG + PD-1 mos 33.4 mnths Demnstrated mutant RASspecific immune activatin First safety review, incl. immune activatin data (3 pts) TBD 1H 2019 Immune activatin and mechanistic data (mn) 1H 2019 TG02 + in viv data 1 Current standard f care chemtherapy fr patients with unresectable malignant pleural mesthelima 2 Patients with advanced peritneal disease, wh have failed prir standard chemtherapy and have histlgically cnfirmed platinum-resistant r refractry epithelial varian r clrectal cancer 3 Trials spnsred by cllabratrs Onging cllabratr spnsred trials 25 25
26
Activating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. 4Q and Full Year August 14 February
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin 4Q and Full Year 2018 fight cancer August 14 February 2019 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains
More informationActivating the immune system to fight cancer. ABG Sundal Collier Oslo 12 June 2018
Activating the immune system t fight cancer ABG Sundal Cllier Osl 12 June 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements based n uncertainty, since they relate t
More informationActivating the immune system to fight cancer
Activating the immune system t fight cancer RedEye pre-asco seminar Erik Digman Wiklund, CFO 28 May 2018 Frm a sequential treatment strategy directly targeting the cancer 1 Surgery When pssible, surgical
More informationActivating the immune system to fight cancer
Activating the immune system t fight cancer Jefferies Investr Cnference New Yrk City Dr. Magnus Jäderberg - CMO 6 June 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements
More informationImportant NOTICE AND DISCLAIMER
1 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements based n uncertainty, since they relate t events and depend n circumstances that will ccur in future and which, by their
More informationActivating the patient s immune system to fight. system to. Company overview. Company presentation. fight cancer. January 2019.
Activating the patient s the immune system t fight immune cancer system t Cmpany verview Cmpany presentatin fight cancer January 2019 August 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains certain
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationArming the immune system to fight cancer
Arming the immune system t fight cancer June 2017 www.targvax.cm Imprtant ntice and disclaimer This reprt cntains certain frward-lking statements based n uncertainty, since they relate t events and depend
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationPress Release. Adocia: Activity and results for the first half of 2013
Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result
More informationArming the patient s immune system to fight cancer. Q presentation
Arming the patient s immune system to fight cancer Q1 2017 presentation April 25 th 2017 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationINTERIM REPORT JANUARY SEPTEMBER 2017
INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap):
More informationPress Release. Adocia Reports Operational and Financial Results for the First Half of 2014
Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin
More informationREPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE
REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationInvestor Presentation
Investr Presentatin May 2018 nclyticsbitech.cm TSX ONC OTCQX ONCYF Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s business prspects and the develpment
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationONCOS-102 in mesothelioma. Dr Magnus Jaderberg Chief Medical Officer Targovax
ONCOS-102 in mesothelioma Dr Magnus Jaderberg Chief Medical Officer Targovax ONCOS CLINICAL DEVELOPMENT STRATEGY 1 2 3 4 Path-to-market Mesothelioma Proof-of-concept CPI refractory Proof-of-concept New
More informationIndependent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More informationResponse to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines
Respnse t type 2 vaccine-derived pliviruses prir t glbal topv withdrawal Interim Guidelines August 2015 GPEI peratinal guidance nte August 2015 Summary Prepare fr prmpt actin fr any area r ppulatin at
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationA Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013
A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationInvestor Presentation
Investr Presentatin August 2018 nclyticsbitech.cm Nasdaq ONCY TSX ONC Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s business prspects and the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST
ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST 7 th July 2017 Cntent 1 Intrductin 2 Tpics fr EOI in the 4 th call 3 The applicatin prcess and imprtant dates 4 Guideline fr EOIs Deadline
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationInvestor Presentation
Fr persnal use nly Investr Presentatin Dr. Marie Rskrw, CEO & Managing Directr September 2014 ASX: PAB Fr persnal use nly Safe Harbur Statement This presentatin cntains frward-lking statements that are
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationPancreatic Cancer Treatment Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The rising prevalence f besity, alchl cnsumptin, and smking is expected t prpel
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationArming the immune system to fight cancer
Arming the immune system to fight cancer Capital Markets Update June 8 th 2017 www.targovax.com Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty,
More informationPandemic H1N1 2009: DrillSafe Update. David Blizzard BD Manager, Energy Mining and Infrastructure
Pandemic H1N1 2009: DrillSafe Update David Blizzard BD Manager, Energy Mining and Infrastructure Pandemic H1N1 Update CDC.Gv USA Pandemic H1N1 Summary Pints Virus cntinues t spread with nearly all WHO
More information12 th European International Kidney Cancer Symposium April 2017
PEGylated Human IL-1 (AM1) in Cmbinatin with Nivlumab in Renal Cell Cancer Aung Naing, Jeffrey R. Infante, Debrah J. Wng, W. Michael Krn, Raid Aljumaily, Kyriaks P. Papadpuls, Karen A. Auti, Shubham Pant,
More informationiprex Fact Sheet: Key Results
EMBARGOED UNTIL RELEASE Tuesday, 23 Nvember 2010, 8 a.m. EST CONTACT Mark Aurigemma; 646-270-9451; mark@aucmm.net Pedr Gicchea; 415-490-8350 pgicchea@gladstne.ucsf.edu iprex Fact Sheet: Key Results iprex
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationOverall Survival and Safety Profile of YERVOY in Patients with Unresectable or Metastatic Melanoma
FDA Apprves YERVOY (ipilimumab) fr the Treatment f Patients with Newly Diagnsed r Previusly-Treated Unresectable r Metastatic Melanma, the Deadliest Frm f Skin Cancer First and Only Apprved Therapy fr
More informationVIRGINIA OBSTETRICS & GYNECOLOGY, P.C.
VIRGINIA OBSTETRICS & GYNECOLOGY, P.C. 19490 Sandridge Way Suite 350 Leesburg, VA 20176 Phne (703) 858-5599 Fax (703) 858-5699 PERSONAL INFORMATION: PATIENT INFORMATION SHEET Please Print Date. Patient's
More informationModule 6: Goal Setting
Mdule 6: Gal Setting Objectives T understand the cncept f gal setting in Brief CBT T acquire skills t set feasible and apprpriate gals in Brief CBT What is gal setting, and why is it imprtant t set gals
More informationAngiography Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Angigraphy Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal angigraphy devices market size was valued at USD 9.8 billin in 2018 and is prjected
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationCnsideratin fr Optimizatin: Optimizatin is a prgram transfrmatin technique, which tries t imprve the cde by making it cnsume fewer resurces (i.e. CPU, Memry) and deliver high speed. In ptimizatin, high-level
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More informationIndirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version
Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...
More informationWCPT awards programme 2015
WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.
More informationMGPR Training Courses Guide
MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,
More informationLee County Florida Income Guideline Chart
NEIGHBORHOOD STABILIZATION PROGRAM OF LEE COUNTY BUYER-RELATED QUESTIONS 1. Why is NSP beneficial t yur buyers? Three key advantages make the NSP Prgram especially attractive t eligible buyers: 1) Investrs
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More informationEAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL
EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL Cncussin awareness has increased significantly in recent years. The Natinal Cllegiate Athletic Assciatin (NCAA), Natinal Athletic Trainers Assciatin
More informationOxford Immunotec Company Overview
Oxfrd Immuntec Cmpany Overview Nvember, 2015 Dr. Peter Wrightn-Smith, Chief Executive Officer Rick Altieri, Chief Financial Officer Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire,
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationneuropharmaceuticals commericalization
neur neurpharmaceuticals cmmericalizatin neurnan pharma 11th Annual NanBusiness Cnference Nanmanufacturing Summit September 4-6, 2012 Bstn, MA neur I. Intrductin 2 Alexander Kabanv, C-funder UNC - Chapel
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationXX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Pembrlizumab NDC CODE(S) 00006-3026-XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME) DESCRIPTION Pembrlizumab is a human prgrammed death
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationInternational Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant
IAEA-CN-233 Internatinal Experts Meeting n Severe Accident Management in the Light f the Accident at the Fukushima Daiichi Nuclear Pwer Plant Organized in cnnectin with the implementatin f the IAEA Actin
More informationTranscatheter Embolization And Occlusion Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Transcatheter Emblizatin And Occlusin Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal Transcatheter Emblizatin and Occlusin (TEO) devices
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationAncillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.
Ancillary Sympsia Request fr Prpsals Partnerr with the Endcrine Sciety t Educate the Endcrine Cmmunity. Jin the Endcrine Sciety in Bstn fr the 98 th Annual Meeting & Exp frm April 1 4, 2016. ENDO 2016
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationState Health Improvement Plan Choosing Priorities, Creating a Plan. DHHS DPH - SHIP Priorities (Sept2016) 1
State Health Imprvement Plan 2017-2021 Chsing Pririties, Creating a Plan DHHS DPH - SHIP Pririties (Sept2016) 1 Creating a Plan: 2017-2021 SHIP Welcme! Wh s here? What is the State Health Imprvement Plan
More informationRisk factors in health and disease
Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk
More informationCode of Conduct for Employees
Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationFrontier School of Innovation District Wellness Policy
Frntier Schl f Innvatin 6700 Crprate dr. Suite 150 Phne: 816-363-1907 http://www.kcfsi.rg/ Frntier Schl f Innvatin District Wellness Plicy The Bard prmtes healthy schls, by supprting wellness, gd nutritin,
More informationImpacts of State Level Dental Hygienist Scope of Practice on Oral Health Outcomes in the U.S. Population
Impacts f State Level Dental Hygienist Scpe f Practice n Oral Health Outcmes in the U.S. Ppulatin Building Trust in Peple and Places C-spnsred by: Prfessinal Standards Authrity Centre fr Trust, Peace and
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More informationProtocol Abstract and Schema
NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD-0332991 (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationCorporate Overview. November 2017 NASDAQ:ACHN Achillion Pharmaceuticals. All rights reserved.
Nvember 2017 2017 Achillin Pharmaceuticals. All rights reserved. NASDAQ:ACHN Cautinary Nte Regarding Frward-Lking Statements This presentatin includes frward-lking statements within the meaning f the Private
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationThe U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria
The U.S. & The Glbal Fund t Fight AIDS, Tuberculsis and Malaria The Glbal Fund t Fight AIDS, Tuberculsis and Malaria (Glbal Fund) is an independent, multilateral, financing entity designed t raise significant
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationPatrys To Present at the 12 th Annual BIO Investor Forum
ASX & Media Release Patrys T Present at the 12 th Annual BIO Investr Frum Melburne, Australia; 9 Octber, 2013: Patrys Limited (ASX: PAB), a clinical stage bitechnlgy cmpany tday annunced that Dr. Marie
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationAnnual Assembly Abstract Review Process
Annual Assembly Abstract Review Prcess AAHPM and HPNA cllabrate t review and select abstracts fr Annual Assembly. The cmmittees meet prir t the calls t review and update the Assembly bjectives (Planning
More information